NR1I2 and metabolic disease: Convergent evidence from human biopsy samples and mice model studies demonstrates that activation of intestinal PXR upregulates the expression of its target gene, β-1,3-galactosyltransferase 5 (B3galt5), thereby preserving the integrity of the intestinal barrier and preventing metabolic disorders induced by barrier dysfunction [51].